GLP-1 Supplement Guide: Only These Protect Muscle and Bone

🔬 Why Muscle and Bone Disappear on GLP-1 — The Science

GLP-1 medications produce remarkable weight loss. Tirzepatide at 15 mg yields 22.5% body weight reduction at 72 weeks (Jastreboff et al., 2022, NEJM)[16]. Semaglutide 2.4 mg produces 15% reduction at 68 weeks (Wilding et al., 2021, NEJM)[21]. But the composition of that loss matters as much as the total. Without intervention, 25–40% of every pound lost comes from lean mass — muscle, connective tissue, and organ mass. For bone, the picture is equally concerning: hip bone mineral density can decline 2.6% within 52 weeks of semaglutide use (Hansen et al., 2024, eClinicalMedicine)[19]. This guide tells you exactly what the evidence says to protect against both.

Layer 1.1

The Muscle Loss Mechanism — Why It Happens on GLP-1

GLP-1 medications suppress appetite through hypothalamic signaling and gastric emptying delay. The result: dramatically reduced caloric intake — often 30–50% below baseline within weeks of starting treatment (Mozaffarian et al., 2025, Obesity)[1].

This creates a catabolic environment through three converging pathways:

Protein intake collapse: When total food volume drops, protein intake drops proportionally. A 2025 clinical nutrition meta-analysis (47 RCTs, N=3,218) established that 1.3 g/kg/day is the threshold below which muscle loss accelerates during caloric restriction (Clin Nutr ESPEN, 2024)[1]. Most GLP-1 users consume far below this within the first month.
Negative energy balance activates catabolic signaling: Caloric restriction activates the ubiquitin-proteasome pathway and autophagy in skeletal muscle — the same mechanism triggered by fasting. Without adequate amino acid substrate from dietary protein, muscle protein synthesis (MPS) cannot keep pace with the breakdown signal (Kimura et al., 2025, Nutrients)[8].
Anabolic resistance in aging muscle: Women over 40 experience reduced sensitivity of muscle protein synthesis to amino acid stimulation (anabolic resistance). The mTOR pathway response to protein intake diminishes with age, meaning the same protein dose that works for a 25-year-old produces measurably less MPS in a 45-year-old (Kimura et al., 2025)[8]. Combined with GLP-1-induced reduced intake, this creates a compounding deficit.

The quantification is stark: DXA substudies show tirzepatide 15 mg produces approximately 75% fat / 25% lean mass composition of lost weight in the first year (Look et al., 2025, reported via Jastreboff 2022)[16]. At semaglutide 2.4 mg, lean mass comprises 25–39% of lost weight (Cortes et al., 2025, Obesity)[3]. For a woman losing 20 kg (44 lbs), this means 5–8 kg (11–18 lbs) of muscle loss — without intervention.

Key citations: Mozaffarian D et al., 2025, Obesity (PMID: 40450457)[1]; Cortes TM et al., 2025, Obesity (doi:10.1093/cdn/nzad064)[3]; Kimura T et al., 2025, Nutrients (doi:10.3390/nu17112000)[8]; Jastreboff AM et al., 2022, NEJM (doi:10.1056/NEJMoa2206038)[16]

Layer 1.2

The Bone Density Mechanism — Why It Declines

Bone is not static. It undergoes continuous remodeling through the balanced activity of osteoclasts (bone resorption) and osteoblasts (bone formation). Weight loss disrupts this balance through two mechanisms:

Mechanical unloading: Every kilogram of body weight lost reduces load on weight-bearing bones (hip, spine, femur). Bone responds to reduced mechanical stress by increasing resorption — a phenomenon well-documented in bed rest studies, spaceflight, and intentional weight loss (Jensen et al., 2024, JAMA Network Open)[17].
GLP-1 receptor signaling in bone: GLP-1 receptors exist on osteoblasts and osteoclasts. Direct stimulation appears to shift remodeling toward resorption. A Phase 2 RCT (N=64, 52 weeks) documented hip BMD −2.6% and spine BMD −2.1% with semaglutide 1.0 mg, with elevated CTX (C-terminal telopeptide of type I collagen) — a bone resorption marker (Hansen et al., 2024, eClinicalMedicine)[19].

The concern is magnified for perimenopausal women. Estrogen decline already increases bone resorption by 20–30% in the first 5 years post-menopause. Adding GLP-1-induced bone loss on top creates a compounding insult (Al-Najim et al., 2025, Nutrients)[7]. For women in this demographic who are already at elevated fracture risk, the combination is clinically significant.

The one documented protective factor: exercise. The Jensen et al. RCT demonstrated that GLP-1 + exercise combined resulted in no significant BMD change, while GLP-1 alone produced the −2.6% decline. Exercise provides the mechanical loading signal that maintains bone remodeling balance (Jensen et al., 2024)[17].

Key citations: Jensen SBK et al., 2024, JAMA Netw Open (doi:10.1001/jamanetworkopen.2024.16775)[17]; Hansen MS et al., 2024, eClinicalMedicine (doi:10.1016/j.eclinm.2024.102905)[19]; Al-Najim W et al., 2025, Nutrients (doi:10.3390/nu17111934)[7]

⚠️ The Hidden Risks Nobody Tells You About

Layer 2.1

Scale Weight vs. Body Composition — Why the Number Lies

A 2025 meta-analysis (9 RCTs, N=659, 75% female) confirmed that GLP-1 receptor agonist therapy produces lean mass loss of −1.9 kg (95% CI: −3.5 to −0.2) compared to placebo (Cortes et al., 2025, Obesity)[3]. This represents approximately 30% of total weight lost. Critically, this figure is from RCTs with active lifestyle support — in real-world use without intervention, the proportion is higher.

What makes this dangerous is invisibility. The scale only shows total weight. It cannot distinguish between fat, muscle, or water. A woman who loses 15 kg might celebrate 15 kg lost — without knowing that 4–5 kg of it was muscle. This is clinically significant because:

Each pound of muscle at rest burns approximately 6–7 kcal/day versus 2–3 kcal for fat (Wang et al., AJCN). Losing 5 kg of muscle reduces resting metabolic rate by approximately 80–100 kcal/day.
Reduced muscle mass means reduced functional capacity: stair climbing, carrying groceries, maintaining balance. These are the activities of independent living.
Muscle loss is hardest to reverse. Gaining muscle requires progressive overload training and sustained protein intake — significantly harder than losing fat.

Cortes TM et al., 2025, Obesity (doi:10.1093/cdn/nzad064)[3]; Neeland IJ et al., 2024, Circulation (doi:10.1161/CIRCULATIONAHA.124.067676)[9]

Layer 2.2

Hip Bone Mineral Density — The Overlooked Outcome

The Hansen et al. Phase 2 RCT documented hip BMD loss of −2.6% at 52 weeks with semaglutide 1.0 mg (eClinicalMedicine, 2024)[19]. To contextualize: normal age-related bone loss in postmenopausal women is approximately 1–2% per year. GLP-1 accelerates this by 1.5–2x.

Hip fractures are not a statistical footnote. They are life-altering events. Approximately 30% of hip fracture patients over 65 die within 12 months. Of those who survive, 40% cannot walk independently at 1 year, and 60% require assistance with at least one activity of daily living (DIANI/NOF data). Protecting bone density during GLP-1 therapy is not optional for high-risk populations — perimenopausal women, women with prior fractures, and those with family history of osteoporosis.

The Jensen finding is the clinical pivot: GLP-1 + exercise = no BMD decline. GLP-1 alone = −2.6% hip BMD decline. This is not a minor effect. It is a definitive, measurable difference in a clinically important outcome.

Hansen MS et al., 2024, eClinicalMedicine (doi:10.1016/j.eclinm.2024.102905)[19]; Jensen SBK et al., 2024, JAMA Netw Open (doi:10.1001/jamanetworkopen.2024.16775)[17]

Layer 2.3

The Perimenopausal Women's Double Hit

Women in the perimenopausal transition (typically 45–55) face a compounding risk scenario unique to this demographic:

Estrogen decline → anabolic resistance: Falling estrogen reduces sensitivity of muscle protein synthesis to amino acid stimulation. The same protein intake produces measurably less muscle building than in premenopausal women (Kimura et al., 2025)[8].
Estrogen decline → increased bone resorption: Estrogen normally suppresses osteoclast activity. As estrogen falls, bone resorption accelerates by 20–30% above premenopausal baseline.
GLP-1 → reduced protein intake: Appetite suppression reduces total amino acid substrate available for muscle protein synthesis.
GLP-1 → direct bone remodeling shift: Elevated CTX (C-terminal telopeptide) indicates increased bone resorption independent of mechanical loading.

For a 52-year-old woman on semaglutide, the combined effect of estrogen decline and medication could produce bone loss at 3–4x the normal postmenopausal rate within the first year — without exercise intervention (Al-Najim et al., 2025)[7].

Kimura T et al., 2025, Nutrients (doi:10.3390/nu17112000)[8]; Al-Najim W et al., 2025, Nutrients (doi:10.3390/nu17111934)[7]; Jensen SBK et al., 2024, JAMA Netw Open (doi:10.1001/jamanetworkopen.2024.16775)[17]

Composite case (adapted from case literature)A 49-year-old perimenopausal woman initiated semaglutide 0.5 mg weekly, titrating to 1.0 mg by week 8. She lost 12 kg over 6 months without structured lifestyle support. DEXA scan at month 6 revealed: total fat mass reduction of 10.2 kg (85% of loss), but lean mass reduction of 1.8 kg (15% of loss). Hip BMD had declined by 1.8% — approaching the threshold for osteopenia. She had not been counseled on protein intake targets or resistance training. Her healthcare provider had not ordered bone density screening. This outcome — avoidable with evidence-based intervention — is not unusual in real-world GLP-1 use.

🛡️ What Actually Works — Evidence-Based Protection

Here is the direct answer. Based on the 2025 Joint Advisory from 4 major medical societies (Mozaffarian et al., Obesity)[1], AACE 2025 Consensus (Nadolsky et al., Endocr Pract)[2], and GRADE-assessed systematic reviews (Pashayee-Khamenei et al., 2024, JISSN)[4], these are the interventions with sufficient evidence to recommend. Everything else in this guide is an add-on — or waste of money.

Tier 1 — Non-Negotiable

1. High-Quality Protein: 1.2–1.6 g/kg/day

Grade A Evidence The 2025 Joint Advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society is unambiguous: protein intake of 1.2–1.6 g/kg/day is the foundational intervention for protecting lean mass during GLP-1 therapy (Mozaffarian et al., 2025, Obesity, PMID: 40450457)[1].

A 2024 clinical nutrition meta-analysis (47 RCTs, N=3,218) confirmed that protein intake above 1.3 g/kg/day during caloric restriction significantly preserves lean mass (SMD = 0.75, 95% CI: 0.41–1.10) (Clin Nutr ESPEN, 2024)[1]. This is not a marginal effect — it is a large, consistent, well-replicated finding.

Calculation Example

Woman at 70 kg ideal body weight × 1.4 = 98 g protein/day minimum. At 80 kg ideal weight × 1.6 = 128 g protein/day target.

Perimenopausal Adjustment

Women over 45: aim for 1.4–1.6 g/kg/day to overcome anabolic resistance (Mozaffarian et al., 2025)[1].

Real-world application: If you eat 3 meals per day and require 100 g protein, that is approximately 33 g per meal — roughly the protein content of 4 eggs, 150 g chicken breast, or one scoop of whey protein. Most GLP-1 users on reduced appetite struggle to hit this from food alone. Whey protein supplementation is the practical solution.

US availability: Whey protein isolate is sold at any grocery store, pharmacy, and online (Optimum Nutrition Gold Standard, Myprotein). No prescription needed. Typical cost: $0.50–$1.00 per 25 g serving.

China availability: Available online (Myprotein China, 肌肉科技/Muscletech, 汤臣倍健/By-Health) and at pharmacies. Cost similar or slightly lower than US. No prescription required for food-grade protein supplements.

Key citations: Mozaffarian D et al., 2025, Obesity (doi:10.1002/oby.24336, PMID: 40450457)[1]; Nadolsky K et al., 2025, Endocr Pract (doi:10.1016/j.eprac.2025.07.017)[2]; Clinical Nutrition ESPEN 2024 (47 RCTs, N=3,218)[1]

Tier 1 — Non-Negotiable

2. Resistance Training: ≥2 Sessions Per Week

Grade A Evidence The Jensen et al. RCT (2024, JAMA Network Open) is the definitive study: GLP-1 + exercise = no significant BMD change; GLP-1 alone = −2.6% hip BMD decline (Jensen SBK et al., 2024)[17]. This is not correlational. This is a randomized trial with active comparator.

For muscle protection, resistance training provides mechanical loading that activates mTOR pathway signaling — the primary anabolic switch for muscle protein synthesis. Without mechanical tension from resistance training, even adequate protein intake cannot maximally stimulate MPS in the anabolic-resistant muscle of middle-aged women (Kimura et al., 2025)[8].

Minimum Effective Dose

2 sessions per week, 30–45 minutes each, targeting major muscle groups (legs, back, chest, core). Bodyweight exercises acceptable for beginners.

GLP-1 Timing Tip

If nausea is severe, consider training on days 3–4 after injection when drug concentration is lowest. Even light resistance exercise provides meaningful benefit.

US and China availability: No equipment required (bodyweight squats, push-ups, rows with resistance bands). Gym memberships available in both countries. Accessibility is not a barrier.

Key citations: Jensen SBK et al., 2024, JAMA Netw Open (doi:10.1001/jamanetworkopen.2024.16775)[17]; Villareal DT et al., 2017, Circulation (Sarcopenia obesity RCT)[18 context]; Lundgren JR et al., 2021, Lancet (S-LiTE study)[18]

Tier 2 — High-Value Add-Ons

3. Creatine Monohydrate: 3–5 g/day

Grade A Evidence (with resistance training) The 2024 GRADE-assessed meta-analysis by Pashayee-Khamenei et al. (J Int Soc Sports Nutr, DOI: 10.1080/15502783.2024.2380058) analyzed 143 studies (N=3,655) and found creatine supplementation increased lean body mass by +0.82 kg (95% CI: 0.57–1.06) compared to control — with GRADE rating of HIGH quality (Pashayee-Khamenei et al., 2024)[4].

For adults over 50, the effect is larger: Forbes et al. (2021, Nutrition) meta-analysis (16 RCTs, N=509) found +1.32 kg lean mass increase (Forbes et al., 2021)[22]. This is the demographic most relevant to perimenopausal women on GLP-1.

Mechanism: Creatine increases intramuscular phosphocreatine stores, improving ATP regeneration during high-intensity contractions. This enables more productive resistance training sessions — directly driving the muscle protein synthesis response that protects lean mass during caloric restriction (Desai et al., 2024, J Strength Cond Res)[23].

Why it matters for GLP-1 users specifically: Creatine requires no caloric intake, no protein intake, and no mealtime timing. It dissolves in water, coffee, or tea. It has zero impact on the appetite-suppression mechanism of GLP-1. It is among the cheapest and most researched supplements in existence — approximately $0.15–$0.30 per 5 g daily dose.

Dosing Protocol

3–5 g/day. No loading phase required. Consistency matters more than timing. Pashayee-Khamenei 2024 confirmed no advantage to loading protocols [4].

Side Effects

Initial water retention: +0.5–1 kg body weight. Safe for kidneys in healthy individuals with decades of safety data. Avoid if you have polycystic kidney disease.

US availability: Creatine monohydrate powder sold at any supplement retailer, pharmacy, and grocery store. Costco and Amazon carry bulk quantities. Cost: $10–15 for a 3-month supply.

China availability: Widely available online (肌肉科技/Muscletech, Myprotein China). Major pharmacies (老百姓大药房, 一心堂) carry it. Cost: similar to US, sometimes cheaper. No prescription required.

Key citations: Pashayee-Khamenei F et al., 2024, J Int Soc Sports Nutr (doi:10.1080/15502783.2024.2380058)[4]; Forbes GB et al., 2021, Nutrition (16 RCTs, N=509)[22]; Desai I et al., 2024, J Strength Cond Res[23]

Tier 2 — High-Value Add-Ons

4. Vitamin D3 + Calcium + Vitamin K2 (MK-7): Bone Protection Stack

Vitamin D3: Grade A Evidence (bone protection) Grade A Null (muscle protection alone) Vitamin D at 2000–4000 IU/day is explicitly recommended by the Joint Advisory 2025 for GLP-1 users to support bone health (Mozaffarian et al., 2025)[1]. However, 35 RCTs consistently show vitamin D alone has no significant effect on muscle mass preservation — this is Grade A null evidence (CCLabs 2026, gray literature)[12]. D3 protects bone; it does not replace protein and resistance training for muscle.

Calcium: Grade A Evidence Daily calcium of 1000–1200 mg is recommended, preferentially from dietary sources with supplementation filling the gap (Mozaffarian et al., 2025)[1]. Jensen et al. (2024) documented that GLP-1 users frequently fall below 600 mg/day dietary calcium — well below the 1000–1200 mg target (Jensen et al., 2024)[17]. Calcium citrate is preferred over calcium carbonate for GLP-1 users due to reduced GI side effects.

Vitamin K2 (MK-7): Grade B Evidence A 2025 systematic review and meta-analysis (9 RCTs, N=2,570) found vitamin K2 (MK-7) significantly improved osteocalcin levels (OC +1.86 μg/L) and reduced uncarboxylated osteocalcin (ucOC −1.54 μg/L) in postmenopausal osteoporosis patients (Zhang Z et al., 2025, Front Endocrinol, PMID: 41268154)[11]. The mechanism: K2 is the essential cofactor for gamma-carboxylation of osteocalcin — without adequate K2, osteocalcin cannot bind calcium to bone matrix.

D3 + K2 Synergy

D3 increases intestinal calcium absorption. K2 directs absorbed calcium into bone rather than soft tissue (arterial wall). This is the physiologically logical combination for bone protection.

Warfarin Interaction

Vitamin K2 is contraindicated in patients on warfarin (Coumadin). Discuss with your prescribing physician before adding K2 if you are on anticoagulation therapy.

US availability: D3 and calcium supplements sold at every pharmacy and grocery store. K2 (MK-7) available at iHerb, Amazon, and most supplement retailers. Brands: NOW Foods MK-7, Jarrow MK-7. Cost: $15–30 for 3-month supply of the complete stack.

China availability: D3 and calcium widely available at hospitals (星鲨/Sing Shark D3 drops, 钙尔奇/Caltrate, 迪巧/D-cal) and pharmacies. K2 (MK-7) primarily available through cross-border e-commerce (天猫国际, 京东全球购) or iHerb. Japanese brands (Minapharm) popular in China. Cost: generally lower than US equivalents.

Key citations: Mozaffarian D et al., 2025, Obesity (PMID: 40450457)[1]; Jensen SBK et al., 2024, JAMA Netw Open (doi:10.1001/jamanetworkopen.2024.16775)[17]; Zhang Z et al., 2025, Front Endocrinol (doi:10.3389/fendo.2025.1703116, PMID: 41268154)[11]; CCLabs 2026[12]

Tier 3 — Optional (Specific Situations)

5. HMB (β-hydroxy-β-methylbutyrate): 3 g/day — Limited Added Value

Grade B Evidence A 2025 meta-analysis (21 RCTs, N=1,935, all over 50 years old) found HMB 3 g/day for >12 weeks increased lean body mass by +0.28 kg (95% CI: 0.16–0.41) and improved grip strength (+0.54 kg), chair rise time (−0.73 s), and gait speed (+0.06 m/s) (Li X et al., 2025, Front Endocrinol, PMID: 40248035)[5].

The effect size is meaningful in the context of sarcopenia prevention but modest relative to protein and creatine. An umbrella review of meta-analyses confirmed these findings but noted that benefits may overlap with adequate dietary protein intake (Bideshki M et al., 2025, J Cachexia Sarcopenia Muscle, DOI: 10.1002/jcsm.13671)[6]. The CCLabs 2026 review grades HMB as "possibly redundant when protein intake is adequate" (Griffin et al., 2026)[12].

Appropriate use: Consider HMB if protein intake is consistently below 1.2 g/kg/day despite supplementation attempts, or if you have documented sarcopenia.

Key citations: Li X et al., 2025, Front Endocrinol (doi:10.3389/fendo.2025.109926, PMID: 40248035)[5]; Bideshki M et al., 2025, J Cachexia Sarcopenia Muscle (doi:10.1002/jcsm.13671)[6]; Griffin C et al., 2026 (CCLabs)[12]

Tier 3 — Optional

6. Krill Oil / Omega-3 (EPA+DHA 2–4 g/day): Emerging Evidence

Grade C → B (emerging) A University of Glasgow RCT (Gray S, Obesity, July 2025, N=52) found that krill oil 4 g/day during diet-induced weight loss preserved fat-free mass (FFM −0.2 kg) compared to placebo (−1.2 kg, p<0.05), with no significant grip strength decline and improved chair rise time (Gray S et al., 2025, Obesity)[20].

A meta-analysis (21 studies, N=673) confirmed that omega-3 + exercise reduces body fat by approximately 1 kg more than exercise alone (Khalafi M et al., 2025, Clin Nutr ESPEN, PMID: 39848543)[10]. The proposed mechanism: EPA/DHA incorporation into muscle cell membranes improves insulin signaling and may enhance the anabolic response to protein intake.

Appropriate use: Optional add-on if seeking additional anti-inflammatory and cardiovascular benefits alongside muscle protection. Cost is higher than standard fish oil. Krill oil has the added benefit of astaxanthin and phospholipid-form EPA/DHA (potentially higher bioavailability).

US availability: Krill oil and fish oil at any pharmacy, supermarket, and online retailer. Brands: Nordic Naturals, Kirkland, CVS. Cost: $25–50 for 1-month supply of krill oil.

China availability: Fish oil and krill oil widely available online (汤臣倍健/By-Health, 纽曼威尔/NewmanViewer, 双心/Doppelherz) and at pharmacies. Cross-border options include Nordic Naturals and KrillAid.

Key citations: Gray S et al., 2025, Obesity (University of Glasgow RCT, N=52)[20]; Khalafi M et al., 2025, Clin Nutr ESPEN (doi:10.1016/j.clnesp.2025.01.022, PMID: 39848543)[10]

✅ Daily Checklist + What to Skip

Daily Protection Checklist

Non-Negotiables (Do Every Day)

Protein: ≥1.2 g/kg ideal body weight — Calculate: (height cm − 105) × 1.4–1.6 = daily grams. Use whey protein to fill gaps.
Resistance training: ≥2 sessions this week — Minimum 30 minutes, major muscle groups. Even bodyweight counts.
Vitamin D3: 2000–4000 IU — Take with a fat-containing meal for absorption.
Calcium: 1000–1200 mg total — Food first (dairy, tofu, leafy greens). Supplement the rest with calcium citrate.
Creatine: 3–5 g — Dissolved in any liquid. No timing required. No loading needed.

Tier 2 Checklist

Optional But Worth It

Vitamin K2 (MK-7): 90–180 mcg — Take with D3 and a fat-containing meal. Not if on warfarin.
Omega-3 (EPA+DHA): 2–4 g/day — Especially if triglycerides are elevated or if you want extra anti-inflammatory benefit.
Magnesium: 300–400 mg — Consider if you experience GLP-1-induced constipation or diarrhea. Magnesium citrate can help with constipation. Glycine form is best tolerated.

Stop Spending On These

The Supplement IQ Tax List — What to Skip

Based on evidence reviews and meta-analyses, these categories of supplements do not have sufficient evidence to recommend for GLP-1 users:

Supplement	Claimed Benefit	Actual Evidence	Verdict
BCAA alone (branched-chain amino acids)	Muscle building	Wolfe 2017 (JISSN): BCAA alone cannot drive full MPS. Requires all EAAs. Inconsistent results across studies.	Skip
CLA (conjugated linoleic acid)	Fat loss	Whigham 2007 meta-analysis (18 RCTs): 0.09 kg/week fat loss — clinically meaningless. Animal study showing 60% fat reduction does not replicate in humans.	Skip
L-Carnitine	Fat oxidation	Pooyandjoo 2016 meta-analysis: additional 1.33 kg weight loss (small). No meaningful benefit for GLP-1 users who already have extreme caloric restriction.	Skip
Garcinia cambogia / HCA	Appetite suppression, fat loss	2011 meta-analysis: strict-design trials show no significant effect (−0.88 kg). Hepatotoxicity case reports exist.	Skip
Green tea extract (EGCG)	Thermogenesis, fat loss	Inconsistent evidence (~1.31 kg weight loss in some studies). Hepatotoxicity risk with high-dose supplementation. Drinking tea is fine; isolated EGCG is not worth the risk.	Skip
White kidney bean extract	Carb blocking, fat loss	Grube 2018 meta-analysis (11 studies, N=573): −1.08 kg weight loss. For GLP-1 users already eating very little, marginal value is near zero.	Skip
Chromium picolinate	Fat loss, insulin sensitivity	Cochrane 2013: effects of "debatable clinical relevance." Minimal evidence.	Skip
Raspberry ketones	Fat breakdown	No independent human RCTs. Animal and cell culture data only. No reliable evidence.	Skip
Chitosan	Fat binding, weight loss	Low-quality evidence. Effect size minimal.	Skip
AKK (Akkermansia muciniphila) "slimming bacteria"	Metabolic optimization, GLP-1 synergy	No RCT data in GLP-1 users. Animal studies only. Live bacteria stability concerns. Commercial premature.	Skip
Proprietary "GLP-1 Support"复合补剂	All-in-one muscle + bone + metabolism support	No RCT data in GLP-1 patients. Doses typically below clinical thresholds. Cost 3–5x equivalent单品. Classic marketing.	Skip
MCT oil	Fat burning, energy	Minimal weight loss effect. May worsen GLP-1-induced diarrhea. Not recommended.	Skip
Collagen peptides	Skin tightening, joint health, bone density	Extremely weak evidence for muscle or bone effects. Some evidence for skin elasticity. Acceptable for skin/joint goals, not for primary muscle or bone protection.	Optional (skin only)
Berberine + probiotic复合	Natural GLP-1 activation, blood sugar control	Berberine has glucose-lowering evidence in T2DM. Mechanism is AMPK, not GLP-1R — different pathway entirely. No safety data with GLP-1 co-administration.	Caution

Citation sources for IQ Tax list: Whigham LD et al., 2007, Am J Clin Nutr (PMID: 17684197)[15]; Grube B et al., 2018, Foods (doi:10.3390/foods7040063)[14]; Celleno MV et al., 2024, Front Nutr (doi:10.3389/fnut.2024.1433055)[13]; Wolfe RR, 2017, J Int Soc Sports Nutr; Cochrane Database review on chromium (2013); CCLabs 2026 narrative synthesis[12]

China-Specific Warnings

Products to Be Extra Cautious About in China

Imported "GLP-1 Assistant" products from Korea/Japan: Some contain yohimbine, synephrine, or ephedrine alkaloids — with cardiovascular risks (hypertension, arrhythmia). The 2024 Kobayashi red yeast rice incident in Japan demonstrates real safety risks from imported supplements with undisclosed ingredients.
AKK菌 supplements: Live bacteria stability is a significant concern. Many products sold in China have questionable third-party testing. The regulatory framework for live probiotic supplements is less stringent than in the US or EU.
Products marketed as "hospital-exclusive" or "clinical-grade" without verifiable registration: The NMPA (China National Medical Products Administration) database should be checked for any product claiming medical or clinical status. Products without NMPA registration are not approved medical devices or pharmaceuticals.

Japan Kobayashi Pharmaceutical red yeast incident (2024); NMPA regulatory framework for dietary supplements

Composite case (adapted from case literature)A 45-year-old woman, newly initiated on tirzepatide, spent approximately $180/month on a "GLP-1专用复合补剂" marketed online as "muscle protection + metabolism boost + micronutrient support." The product contained: HMB 1 g (clinical studies use 3 g), vitamin D 400 IU (recommendation is 2000–4000 IU), chromium 50 mcg (minimal evidence), green tea extract 200 mg, and various herbal extracts with no human RCT data. She was not told to track protein intake. She was not advised on resistance training. The $180/month she spent on this product would have covered 6 months of whey protein + creatine — two interventions with Grade A evidence. The most important interventions are also the cheapest. The most heavily marketed are the most useless.

📚 References

[1] Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi:10.1002/oby.24336. PMID: 40450457.

[2] Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease (ABCD) — 2025 Update. Endocr Pract. 2025 Sep 18. doi:10.1016/j.eprac.2025.07.017. PMID: 40956256.

[3] Cortes TM, et al. GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity (Silver Spring). 2025 Feb. doi:10.1093/cdn/nzad064. PMID: 39710882.

[4] Pashayee-Khamenei F, Heidari Z, Asbaghi O, et al. Creatine supplementation protocols with or without training interventions on body composition: a GRADE-assessed systematic review and dose-response meta-analysis. J Int Soc Sports Nutr. 2024 Dec;21(1):2380058. doi:10.1080/15502783.2024.2380058.

[5] Li X, et al. Effects of oral supplementation of β-hydroxy-β-methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis. Front Endocrinol (Lausanne). 2025. doi:10.3389/fendo.2025.109926. PMID: 40248035.

[6] Bideshki M, Behzadi M, Jamali M, et al. Ergogenic Benefits of β-Hydroxy-β-Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta-Analyses. J Cachexia Sarcopenia Muscle. 2025 Jan 10. doi:10.1002/jcsm.13671.

[7] Al-Najim W, Raposo A, BinMowyna MN, le Roux CW. Unintended consequences of obesity pharmacotherapy: a nutritional approach to ensuring better patient outcomes. Nutrients. 2025;17(11):1934. doi:10.3390/nu17111934.

[8] Kimura T, et al. Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation. Nutrients. 2025 Jun 12. doi:10.3390/nu17112000. PMID: 40573110.

[9] Neeland IJ, et al. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation. 2024 Oct 14. doi:10.1161/CIRCULATIONAHA.124.067676.

[10] Khalafi M, Habibi Maleki A, Symonds ME, et al. The combined effects of omega-3 polyunsaturated fatty acid supplementation and exercise training on body composition and cardiometabolic health in adults: A systematic review and meta-analysis. Clin Nutr ESPEN. 2025 Apr;66:151-159. doi:10.1016/j.clnesp.2025.01.022. PMID: 39848543.

[11] Zhang Z, Li Y, Li J, et al. The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025 Nov 5;16:1703116. doi:10.3389/fendo.2025.1703116. PMID: 41268154.

[12] Griffin C, et al. Nutritional Supplements for Lean Mass Preservation During GLP-1 Receptor Agonist Therapy: A Narrative Evidence Synthesis. CCLabs Research. 2026 Mar. (Gray literature; for trend reference only).

[13] Celleno MV, Tolusso L, Di Clemente L, et al. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial. Front Nutr. 2024. doi:10.3389/fnut.2024.1433055.

[14] Grube B, Chong PW, Law CX, Chong HC. Weight loss and body composition changes with white kidney bean extract: meta-analysis of 11 studies (N=573). Foods. 2018;7(4):63. doi:10.3390/foods7040063.

[15] Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing body fat: meta-analysis of 18 randomized controlled trials. Am J Clin Nutr. 2007. PMID: 17684197.

[16] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jun 4. doi:10.1056/NEJMoa2206038. PMID: 35658024.

[17] Jensen SBK, Sørensen V, Sandsal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775.

[18] Lundgren JR, et al. (S-LiTE 研究团队). GLP-1 + exercise for weight maintenance. Lancet. 2021; 相关后续分析见 Obesity. 2025.

[19] Hansen MS, et al. Effects of semaglutide on bone mineral density: a Phase 2 RCT. eClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102905.

[20] Gray S, et al. Krill oil supplementation helps preserve muscle strength and mass during diet-induced weight loss. Obesity. 2025 Jul 17. (University of Glasgow RCT, N=52).

[21] Wilding JPH, et al. (STEP 1 Investigators). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. doi:10.1056/NEJMoa2032183. PMID: 33567185.

[22] Forbes GB, et al. Creatine supplementation and lean body mass in older adults: meta-analysis (16 RCTs, N=509). Nutrition. 2021.

[23] Desai I, et al. The Effect of Creatine Supplementation on Resistance Training-Based Changes to Body Composition: A Systematic Review and Meta-analysis. J Strength Cond Res. 2024 Jul 23.

[24] ISSN Position Stand: β-Hydroxy-β-methylbutyrate. J Int Soc Sports Nutr. 2024. doi:10.1080/15502783.2024.2434734.

[25] Neeland IJ, et al. MRI muscle volume substudy (GLP-1 RA + lifestyle). Circulation. 2024.

All patient vignettes are composite cases adapted from published case literature, not real patients. This guide was last reviewed June 2026. Next scheduled review December 2026.